Business · 24/07/2026Updated: 10/17/2026 · 1 min read
FDA Classifies Prognostic Test for Chronic Kidney Disease Progression into Class II
Summary
The FDA has classified the prognostic test for assessing chronic kidney disease progression into Class II, a move expected to reduce regulatory burdens and enhance patient access to innovative devices.
Original source language: Federal Register — Health and Human ServicesOpen original release →